Accepted for/Published in: JMIR Dermatology
Date Submitted: May 18, 2024
Date Accepted: Jun 18, 2024
Date Submitted to PubMed: Jun 18, 2024
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Assessing the Relationship between Vitiligo and Major Depressive Disorder Severity: A Cross-Sectional Study
ABSTRACT
Background:
Vitiligo, a common dermatological disorder in Saudi Arabia, is associated with significant psychological impacts. This study explores the relationship between vitiligo and the severity of Major Depressive Disorder (MDD), highlighting the broader implications on mental health among affected individuals.
Objective:
This study aims to assess the prevalence and predictors of depression among adult vitiligo patients. Moreover, examining the relationship between MDD severity and vitiligo, utilizing the VASI and Patient Health Questionnaire-9 (PHQ-9) scales to assess the extent and severity of both conditions.
Methods:
Employing a cross-sectional design, the research utilized the Vitiligo Area Severity Index (VASI) and the Patient Health Questionnaire-9 (PHQ-9) to measure the extent of vitiligo and depression severity respectively. The study involved 340 diagnosed vitiligo patients from various healthcare settings. Logistic and ordinal regression analysis were applied to evaluate the impact of sociodemographic variables and vitiligo types on MDD severity.
Results:
the prevalence of MDD was 58.8%. The analysis further revealed that depression severity varied notably; 24.7% of patients experienced mild depression, 31.1% moderate, 22.6% moderately severe, and 21.6% severe depression. Female patients, those who are divorced or have lower incomes, and patients with acrofacial or vulgaris types of vitiligo experience more severe depression.
Conclusions:
The findings suggest that vitiligo contributes to an increased risk of severe depression, highlighting the need for integrated dermatological and psychological treatment approaches to address both the physical and mental health aspects of the disease. Clinical Trial: NAD
Citation
The author of this paper has made a PDF available, but requires the user to login, or create an account.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.